Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Tanaka, Y.

Refine Results

Resource Type

Availability

Creation Date

Show more

Author

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 55)

Pages

EULAR recommendations for the management of systemic lupus erythematosus
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept
The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept
Sustained remission and outcomes with abatacept plus methotrexate following stepwise dose de-escalation in patients with early rheumatoid arthritis
Clinical efficacy of sarilumab versus upadacitinib over 12 weeks
Clinical efficacy of sarilumab versus upadacitinib over 12 weeks
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions
Use of platelet inhibitors for digital ulcers related to systemic sclerosis
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4)
Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional antirheumatic drugs
Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase

Pages